Tango Therapeutics Appoints Sung Lee to Board of Directors

Core Insights - Tango Therapeutics, Inc. has appointed Mr. Sung Lee to its Board of Directors, bringing over 20 years of finance leadership experience in the biopharmaceutical and technology sectors [1][2] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on developing precision cancer medicines [1] - The company is advancing its lead program, vopimetostat, into registrational studies [2] Leadership Appointment - Mr. Sung Lee's experience includes serving as Executive Vice President and Chief Financial Officer at Cytokinetics since May 2024, and prior roles at Vir Biotechnology, MorphoSys, and Sangamo Therapeutics [2] - He has a strong background in corporate strategy, investor relations, and finance, which will support Tango's late-stage clinical development activities [2] Educational Background - Mr. Lee holds a bachelor's degree in economics from the University of California, Irvine, and a Master of Business Taxation from the University of Southern California [2]